The Ledger

A private equity duo just bought its way into the exact wearable-driven wellness platform built around the same technology now seeking a 16 billion dollar Wall Street debut. Altas Partners and L Catterton agreed September 10, 2026 to acquire a majority stake in Fullscript, an Ottawa, Ontario based platform used by more than 135,000 healthcare practitioners to manage supplement recommendations, lab orders and patient adherence for roughly 10 million patients a year across North America, buying out prior owners HGGC and Snapdragon Capital Partners after a five year hold. Terms were not disclosed. Fullscript’s growth case leans heavily on a January 2026 partnership with Oura that pipes the ring maker’s wearable biometric data into practitioner workflows, a tie-up that looks more valuable this week now that Oura Health itself filed paperwork September 3, 2026 to go public on the Nasdaq under the ticker OURA, seeking to raise up to 3 billion dollars at a valuation north of 16 billion dollars; Oura’s own filing shows revenue of 1.21 billion dollars for the nine months ended June 30, 2026, up 74 percent year over year, and 5 million paying members. Confidence: High on the Fullscript deal facts and the Oura filing figures, both drawn from the companies’ own disclosures. Medium on how much the pending Oura listing actually shaped Fullscript’s price, since neither company’s own statement drew that connection. Sources: Altas Partners, L Catterton agree to acquire Fullscript from HGGC, PE Hub, Fullscript Announces Strategic Investment from Altas Partners and L Catterton, Business Wire, Oura Inc. Form S-1, SEC EDGAR.

Universal Health Services just told investors that patients who lost Affordable Care Act exchange coverage are not showing up as paying customers somewhere else, they are mostly showing up as unpaid care. At the Wells Fargo 21st Annual Healthcare Conference September 8, 2026, Universal Health Services (UHS) Chief Financial Officer Steve Filton said the unfavorable financial impact from exchange coverage losses has widened to 85 million dollars for 2026 from an earlier 75 million dollar estimate, split roughly 35 million dollars in the first half and 50 million dollars projected for the second, because “rather than seeing folks who lost exchange coverage converting to commercial, it felt like almost a one for one exchange…into uncompensated volume.” UHS also cut its full year adjusted admissions guidance to 1.5 to 2.5 percent growth from 2 to 3 percent and trimmed its behavioral health patient day target to 1 to 2 percent from 2 to 3 percent, even as it flagged malpractice expense, now about 1 percent of revenue, or 175 million to 200 million dollars a year, growing 10 to 15 percent annually against 4 to 5 percent medical inflation. The company’s mid-August 2026 acquisition of teletherapy platform Talkspace, adding about 250 million dollars in annual outpatient revenue and a 6,000 therapist panel, is one of the few line items management still expects to help results. Confidence: Medium-High. This run relied on a trade press transcript of UHS executives’ own conference remarks rather than the company’s own transcript or an 8-K filing. Sources: Universal Health Services at Wells Fargo conference: growth steadies, headwinds linger, Investing.com.

The Department of Veterans Affairs just handed a struggling publicly traded telehealth company its biggest potential lifeline in years. Amwell (NYSE: AMWL) announced September 8, 2026 that the Department of Veterans Affairs (VA) issued a letter of intent naming Amwell to help power a modernization of the department’s digital health infrastructure, potentially deploying Amwell’s virtual care platform across a system serving more than 9 million veterans and replacing aging VA telehealth technology; VA telehealth visits already reached 2.9 million in fiscal year 2025, up 10 percent from the prior year. The letter of intent is not a signed contract, a binding deal still depends on Amwell clearing federal requirements including a review by the VA’s chief information officer, but the announcement alone matters for a stock that has spent years trying to convince investors its government and military contracts can offset losses in its commercial telehealth business. Confidence: High on the letter of intent itself, drawn from Amwell’s own announcement. Low on eventual contract value or timing, which neither Amwell nor the VA has disclosed. Sources: Amwell Receives Letter of Intent from Department of Veterans Affairs to Help Power its Digital Health Infrastructure, GlobeNewswire, Veterans Affairs taps Amwell for telehealth revamp, Healthcare Dive.

The federal government just placed a 62.7 million dollar bet that artificial intelligence can safely prescribe drugs and order lab tests for heart failure patients without a doctor approving every step. The Advanced Research Projects Agency for Health (ARPA-H) announced its Agentic AI-Enabled Cardiovascular Care Transformation (ADVOCATE) program this week, committing 62.7 million dollars over four years, with up to 33.7 million dollars in year one, to build a clinical agentic AI system that ARPA-H wants the Food and Drug Administration (FDA) to eventually authorize as a partially autonomous member of the care team, capable of assessing symptom severity, prescribing medications and ordering labs. Recipients include Kaiser Permanente, Duke University and Stanford University alongside health AI vendors Atman Health, Tempus AI (Nasdaq: TEM) and Updoc; ARPA-H projects that if the program succeeds it could generate an estimated 28 billion dollars in annual savings across the heart failure population alone. Confidence: High on the award structure and recipients, drawn from multiple outlets’ direct reporting on ARPA-H’s announcement. Low on the 28 billion dollar savings figure, which is ARPA-H’s own unverified projection. Sources: ARPA-H to invest 62.7 million dollars in AI bots for heart failure care, STAT, ARPA-H to invest $62M to build agentic AI agent for heart care, Healthcare Dive.

Nearly half of all hospitals in the country no longer deliver babies, and the program that pays for more than four in ten U.S. births is about to get cut. A University of Minnesota Rural Health Research Center report, covered September 10, 2026, found that more than 700 hospitals closed their maternity wards between 2010 and 2024, leaving 57 percent of rural hospitals without a birthing unit as of 2024 and pushing the number of states where at least half of rural obstetric wards have shut from 12 to 31; nearly 36,000 births in 2024 happened at a hospital that would close its maternity ward the following year. The report ties the closures directly to Medicaid, which finances about 41 percent of all U.S. births and, providers say, does not cover the actual cost of running a labor and delivery unit, a math problem about to get harder as Medicaid cuts under last year’s One Big Beautiful Bill Act take effect. Confidence: Medium-High. This run relied on trade press summary of the University of Minnesota center’s report rather than the underlying report itself. Sources: Half of U.S. hospitals lack maternity wards as Medicaid cuts loom: report, Healthcare Dive.

THE DEAL SHEET

Target	Acquirer/Investor	Vertical	Value	Source
Fullscript	Altas Partners and L Catterton	Digital health, integrative care platform	Undisclosed majority stake; announced September 10, 2026	PE Hub
Ambit RD	Danforth Health (Avesi Partners-backed)	Life sciences consulting, rare disease commercialization	Undisclosed; announced September 9, 2026	GlobeNewswire
Santa Barbara Fertility Center	Ivy Fertility (InTandem Capital-backed)	Fertility clinics	Undisclosed; announced September 9, 2026	PR Newswire
Argonaut’s Life Sciences and Diagnostics division (renamed Aluris Sciences)	1315 Capital	Life sciences contract manufacturing	Undisclosed; announced September 9, 2026	BioSpace
Huizhou ForYou Medical Devices (minority stake)	Novo Holdings	Wound care contract manufacturing, China	Undisclosed; announced September 10, 2026	Novo Holdings, PR Newswire via Manila Times

This run’s scan of FTC and DOJ merger actions and state transaction-review dockets found no new healthcare antitrust complaints or consent decrees in the last 24 to 48 hours; the MultiPlan/Claritev out-of-network repricing multidistrict litigation (MDL 3121) remains in fact discovery, with a bellwether trial date now set for December 7, 2027. A frontier check on medical professional liability insurance, a Ledger branch last touched July 26, found no newly dated rate filing, underwriting report or acquisition inside this run’s window. An open-ended scan of this week’s private equity deal flow, drawn from PE Hub’s live feed, surfaced the five transactions above as the window’s most consequential healthcare business signal outside the stories covered above.